(Reuters) - BOSTON, June 18 - After multiple stops and starts, biotechnology company Cephalon Inc. has won U.S. approval for its drug to treat excessive sleepiness in patients with conditions such as obstructive sleep apnea.
The Frazer, Pennsylvania-based company said on Monday that the U.S. Food and Drug Administration approved the drug, Nuvigil, to treat overwhelming sleepiness associated with sleep apnea, narcolepsy and shift work.
Read more at Reuters.com Government Filings News
The Frazer, Pennsylvania-based company said on Monday that the U.S. Food and Drug Administration approved the drug, Nuvigil, to treat overwhelming sleepiness associated with sleep apnea, narcolepsy and shift work.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment